Velcade®, cyclophosphamide and dexamethasone (VCD) and myeloma Infoguide

This Infoguide provides information about bortezomib (Velcade®), cyclophosphamide and dexamethasone (VCD), a treatment combination used in myeloma.

VCD is a treatment combination for myeloma. This combination is also referred to as CyBorD. It is often referred to as ‘chemotherapy’ or ‘chemo’, but it is actually a combination of three different types of drugs:

  • Bortezomib (Velcade®) – a proteasome inhibitor;
  • Cyclophosphamide – a chemotherapy drug;
  • Dexamethasone – a steroid.

These three drugs have different but synergistic and complementary mechanisms of action. This means they work in different ways but when given together they are much more effective at killing the myeloma cells than if they were given alone.

VCD may be used in a number of different settings. It is commonly used as a treatment combination at first relapse.

It may also may be used as an initial treatment for myeloma patients who are contraindicated to thalidomide and are unsuitable for stem cell transplantation or who have poor kidney function.

It can also be used as an induction treatment prior to high-dose therapy and stem cell transplantation (HDT-SCT) in younger and/or fitter myeloma patients who are contraindicated to thalidomide.